Xconomy

SEPTEMBER 27, 2016

San Diego’s Avalon Ventures led the Series A round, and has established Fortis at COI Pharma, the firm’s biotech incubator (which now houses 16 life sciences startups). Lilly Asia Ventures, Osage University Partners, and Vivo Capital joined in the deal, according to a statement from Avalon. 9/27/16, 2:09 p.m. Bregua Corp.,

Avalon 40

Avalon Funding Startup San Diego 40

socalTECH

DECEMBER 6, 2012

San Diego-based Avelas Biosciences has raised $7.65M in a Series A funding round, which it says will go towards clinical studies for its technology for real-time tumor visualization. The funding came from Avalon Ventures. The firm's CEO is currently Jay Lichter, who is also a Managing Director at Avalon Ventures. READ MORE>>.

Avalon 138

Avalon San Diego Study Technology 138

socalTECH

AUGUST 30, 2010

The round was led by Novo Ventures and RiverVest Venture Partners, and also includes Domain Associates, TPG Biotech, and Avalon Ventures. The firm said the new fundings will go to support its programs through clinical studies. in a Series B financing.

Avalon 150

Avalon San Diego Venture Capital Study 150

socalTECH

JUNE 11, 2010

The round came from Avalon Ventures. According to Otonomy, the funding will go towards supporting the ongoing clinical trial for its compound, to initiate IND studies for a second compound, and early-stage development of a third program. Otonomy is headed by Jay Lichter, who is also a managing director at Avalon Ventures.

Avalon 113

Avalon San Diego Study Capital 113

Xconomy

AUGUST 17, 2016

and San Diego’s Avalon Ventures. Avalon Ventures founded Avelas, and has housed the startup with other Avalon biotech startups at its COI Pharmaceuticals R&D facility in San Diego. The Phase 1b study also determined a preferred dose for the next stage in the study. Carmine Stengone.

Avalon 40

Avalon San Diego Study Invest 40

Xconomy

AUGUST 31, 2016

The fluorescing proteins they created made it possible for scientists to study changes in living cells and other organisms, illuminating cellular acidity and gene expression, among other things. Various Fluorescing Proteins.

San Diego 72

San Diego UCSD Avalon Study 72

Xconomy

FEBRUARY 26, 2020

The deal follows completion of a Phase 1 study evaluating the PvP drug. Takeda (NYSE: TAK ) acquired the company for an undisclosed amount up front, plus up to $330 million in payments based on development and regulatory milestones for PvP’s experimental celiac disease drug KUMA062 (now TAK-062).

San Diego 72

San Diego Study Develop Development 72